Effectiveness and Safety of Intermittent Antimicrobial Therapy for the Treatment of New Onset Pseudomonas Aeruginosa Airway Infection in Young Patients With Cystic Fibrosis.

Trial Profile

Effectiveness and Safety of Intermittent Antimicrobial Therapy for the Treatment of New Onset Pseudomonas Aeruginosa Airway Infection in Young Patients With Cystic Fibrosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2013

At a glance

  • Drugs Ciprofloxacin; Tobramycin
  • Indications Cystic fibrosis-associated respiratory tract infections; Pseudomonal infections
  • Focus Therapeutic Use
  • Acronyms EPIC
  • Most Recent Events

    • 04 Dec 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 29 Sep 2011 Status changed from active, no longer recruiting to completed according to results published in Archives of Pediatrics and Adolescent medicine.
    • 01 Sep 2011 Results published in the Archives of Pediatrics and Adolescent Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top